---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-059902"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T16:43:32.208588+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biostage raises $5.1M in private placement to advance esophageal implant clinical trial

## Summary
- Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.
- Warrants exercisable at $8.88/share for 5 years; $4.8M received, $260K expected shortly.
- Proceeds to accelerate FDA-approved 10-patient Phase 1/2 trial of Biostage Esophageal Implant for severe esophageal disease.
- Company also developing Biostage Bronchial Implant for lung cancer and birth defects.
- CEO David Green expressed optimism about advancing pipeline for patients and shareholders.

## SEC filing metadata
- accession: 0001104659-22-059902
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000110465922059902/0001104659-22-059902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000110465922059902/tm2215472d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-059902
- JSON: https://secwatch.observer/filing/0001104659-22-059902.json
- Plain text: https://secwatch.observer/filing/0001104659-22-059902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.